Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ADLYXIN vs OZEMPIC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of endogenous GLP-1, which increases insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. The primary mechanism is activation of GLP-1 receptors on pancreatic beta cells, leading to glucose-dependent insulin release.
Type 2 diabetes mellitus adjunct to diet and exercise
Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,Reduce risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) in adults with type 2 diabetes mellitus and established cardiovascular disease
Subcutaneous injection: 10 mcg once daily within 60 minutes before the first meal of the day; may increase to 20 mcg once daily after 2 weeks.
1 mg subcutaneously once weekly, starting at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for at least 4 weeks before escalating to 1 mg.
Terminal elimination half-life is 2–3 hours after subcutaneous administration, supporting a twice-daily dosing regimen.
Terminal elimination half-life approximately 1 week (5–7 days) in subcutaneous dosing, allowing once-weekly administration. Steady state reached after 4–5 weeks.
Metabolized by dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase; not extensively metabolized by CYP450.
Semaglutide is metabolized via proteolytic cleavage of the peptide backbone and sequential beta-oxidation of the fatty acid side chain. No specific CYP450 enzymes are involved.
Renal (predominantly via glomerular filtration and proteolytic degradation; approximately 35% of the dose is excreted unchanged in urine, with the remainder as metabolites and small peptides).
Primarily renal (80%) and biliary/fecal (20%). Unchanged parent drug accounts for ~5-10%; majority is degraded into small peptides/amino acids.
Approximately 55–65% bound to plasma proteins (albumin and α1-acid glycoprotein).
>99% bound to albumin.
Volume of distribution at steady state is approximately 0.5–1.0 L/kg, indicating distribution into total body water with limited tissue penetration.
Approximately 0.12 L/kg (mean ~8.3 L), indicating limited extravascular distribution and confinement primarily to plasma and interstitial fluid.
Subcutaneous: Absolute bioavailability is approximately 100% due to high absorption from injection site and minimal first-pass metabolism; oral bioavailability is negligible due to rapid proteolytic degradation.
Subcutaneous: 89% (95% CI: 80–97%). Not orally bioavailable due to peptide degradation.
GFR 30-50 m L/min: No dose adjustment. GFR <30 m L/min: Not recommended. End-stage renal disease: Contraindicated.
No dose adjustment required for GFR 30-89 m L/min. Avoid use if GFR < 30 m L/min due to limited data and potential for gastrointestinal adverse effects.
Child-Pugh Class A or B: No dose adjustment. Child-Pugh Class C: Not studied; use with caution.
No dose adjustment recommended for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C); use with caution.
Safety and efficacy not established in pediatric patients; no recommended dose.
Not approved for pediatric patients; no established dosing guidelines.
No specific dose adjustment; monitor renal function and volume status due to increased risk of dehydration and renal impairment.
No specific dose adjustment needed based on age; monitor renal function due to age-related decline and consider cautious titration due to increased risk of gastrointestinal effects and dehydration.
No FDA black box warning.
No FDA black box warning exists for Ozempic.
Risk of thyroid C-cell tumors (medullary thyroid carcinoma), acute pancreatitis, hypoglycemia when used with insulin secretagogues or insulin, renal impairment, gastrointestinal adverse effects, and hypersensitivity reactions.
Risk of thyroid C-cell tumors: Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2).,Acute pancreatitis: Discontinue if suspected.,Diabetic retinopathy complications: Increased risk, especially in patients with a history of retinopathy.,Hypoglycemia: Increased risk when used with insulin or insulin secretagogues.,Renal impairment: Acute kidney injury reported; monitor renal function.,Gastrointestinal effects: Nausea, vomiting, diarrhea; may cause volume depletion.,Hypersensitivity: Serious allergic reactions reported.
Personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, hypersensitivity to lixisenatide or any excipients.
Personal or family history of medullary thyroid carcinoma (MTC),Multiple endocrine neoplasia syndrome type 2 (MEN-2),Known hypersensitivity to semaglutide or any product components,Not for use in type 1 diabetes mellitus or diabetic ketoacidosis
Take once daily within 1 hour before the first meal of the day. Avoid high-fat meals as they may delay gastric emptying and exacerbate GI side effects. No specific food restrictions beyond general diabetes management. Separate oral medications that require rapid absorption (e.g., antibiotics, levothyroxine) by at least 1 hour before or 4 hours after lixisenatide dose.
No specific food interactions. Ozempic delays gastric emptying, which may affect absorption of oral medications. Take oral medications requiring rapid absorption (e.g., antibiotics, oral contraceptives) at least 1 hour before Ozempic injection. No dietary restrictions required, but nausea may be reduced by eating smaller, less fatty meals.
ADLYXIN (lixisenatide) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity, but there are no adequate and well-controlled studies in pregnant women. Due to the physiological changes of pregnancy, including increased blood volume and renal clearance, the drug's effect may be altered. However, based on available data, the risk of major birth defects is not significantly increased compared to the general population. Nevertheless, it should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
No adequate human studies. Animal studies show fetal growth retardation, skeletal anomalies, and increased pregnancy loss at exposures similar to human exposure. Risk cannot be excluded in first trimester. Second and third trimester: potential for fetal pancreatic beta-cell hyperplasia and altered glucose homeostasis.
It is unknown whether lixisenatide is excreted in human breast milk. In animal studies, lixisenatide was detected in milk at low concentrations. The M/P ratio has not been established. Caution should be exercised when administered to a nursing woman, considering the importance of the drug to the mother and the potential for adverse effects on the breastfed infant.
No human data. Excreted in rat milk with M/P ratio unknown. Risk to infant cannot be excluded; consider discontinuing breastfeeding or drug.
No specific dosing adjustments for ADLYXIN are recommended during pregnancy. However, pregnancy can alter glucose metabolism, and insulin requirements often change, particularly in the third trimester. Since ADLYXIN is not the preferred agent for glycemic control in pregnancy (insulin is preferred), dose adjustments should be individualized and based on careful glucose monitoring. If used, the starting dose should be as per prescribing information, with further adjustments guided by blood glucose levels and renal function.
No dose adjustment studied in pregnancy. Pharmacokinetics may be altered due to increased blood volume and renal changes; however, no specific adjustment recommendations exist. Use only if potential benefit justifies risk.
ADLYXIN (lixisenatide) is a GLP-1 receptor agonist for type 2 diabetes. Administer within 1 hour before the first meal of the day; skip dose if meal is skipped. Do not mix with insulin in same syringe. Contraindicated in patients with history of pancreatitis or severe GI disease. Monitor for acute kidney injury, especially if on concomitant ACEi/ARBs or diuretics. Delays gastric emptying; caution with oral medications requiring rapid absorption.
Ozempic (semaglutide) is a GLP-1 receptor agonist for type 2 diabetes. Start at 0.25 mg weekly for 4 weeks, then increase to 0.5 mg. If additional glycemic control needed, may increase to 1 mg after at least 4 weeks. Administer subcutaneously once weekly, any time of day, with or without meals. Missed dose: if >5 days late, skip and resume next scheduled dose. Common side effects: nausea, vomiting, diarrhea, constipation. Risk of hypoglycemia when used with insulin or sulfonylureas; consider dose reduction of these agents. Contraindicated in medullary thyroid carcinoma (MTC) personal/family history or MEN-2. Monitor for pancreatitis and acute kidney injury. May delay gastric emptying; caution with oral medications requiring rapid absorption. Not first-line for weight loss but may promote significant weight reduction.
Inject once daily within 1 hour before your first meal of the day; if you skip that meal, skip the dose.,Store unused pens in the refrigerator (36°F to 46°F); after first use, can store at room temperature for up to 14 days.,Rotate injection sites (abdomen, thigh, upper arm) to reduce bruising or lipodystrophy.,Avoid use if you have severe stomach problems such as gastroparesis or inflammatory bowel disease.,Seek immediate medical attention if you experience severe abdominal pain with nausea/vomiting (possible pancreatitis).,Report symptoms of gallbladder disease (right upper quadrant pain, fever, jaundice).,Do not take if you have a personal or family history of medullary thyroid carcinoma (MTC); alert doctor for neck lump.
Inject Ozempic once a week on the same day, any time of day, with or without food.,Do not share pens even if needle changed; risk of infection transmission.,Store unused pens in refrigerator (36°F to 46°F); in-use pen can be stored at room temperature (59°F to 86°F) for up to 56 days.,Rotate injection sites (abdomen, thigh, upper arm) to avoid lipodystrophy.,Report persistent severe abdominal pain (possible pancreatitis) or vision changes (possible diabetic retinopathy complications).,If you miss a dose, take it within 5 days of missed dose; if more than 5 days, skip and resume next scheduled dose.,Take oral medications at least 1 hour before Ozempic injection if delayed gastric emptying is a concern.,Do not drive or operate machinery until you know how Ozempic affects you, as dizziness may occur.,Carry a fast-acting sugar source (e.g., glucose tablets) if also using insulin or sulfonylureas.,Weight loss is possible but not the primary FDA-approved indication; discuss weight management goals with your provider.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ADLYXIN vs OZEMPIC, answered by our medical review team.
ADLYXIN is a GLP-1 Receptor Agonist that works by Glucagon-like peptide-1 (GLP-1) receptor agonist; increases insulin secretion, decreases glucagon secretion, slows gastric emptying, and promotes satiety.. OZEMPIC is a GLP-1 Receptor Agonist that works by Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist. It mimics the action of endogenous GLP-1, which increases insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety. The primary mechanism is activation of GLP-1 receptors on pancreatic beta cells, leading to glucose-dependent insulin release.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ADLYXIN and OZEMPIC depend on the specific clinical indication. These are both GLP-1 Receptor Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ADLYXIN is: Subcutaneous injection: 10 mcg once daily within 60 minutes before the first meal of the day; may increase to 20 mcg once daily after 2 weeks.. The standard adult dose of OZEMPIC is: 1 mg subcutaneously once weekly, starting at 0.25 mg once weekly for 4 weeks, then 0.5 mg once weekly for at least 4 weeks before escalating to 1 mg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ADLYXIN and OZEMPIC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ADLYXIN is classified as Category C. ADLYXIN (lixisenatide) is classified as FDA Pregnancy Category B. Animal studies have shown no evidence of teratogenicity, but there are no adequate and well-controlled studies in . OZEMPIC is classified as Category C. No adequate human studies. Animal studies show fetal growth retardation, skeletal anomalies, and increased pregnancy loss at exposures similar to human exposure. Risk cannot be exc. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.